GmPcides, a new class of bactericidal small molecules

Important results from the project

** Denna text är maskinöversatt ** The overall objective of the project is to develop new small molecules for the treatment of antibiotic-resistant infections caused by Gram-positive bacteria. These so-called GmPcides have the ability to enhance the effect of existing antibiotics and our objective is that the substances should be used to treat healthcare-related infections where antibiotic resistance is a growing problem that threatens all modern healthcare and we have now taken several important steps to approach this objective.

Expected long term effects

** Denna text är maskinöversatt ** We have made great progress in identifying and evaluating new compounds that could be the start of a new class of antibiotics. We have performed extensive tests of the compounds´ activity against a spectrum of Gram-positive bacteria, including multiresistant strains. This has contributed to increased knowledge about the effect, mechanism of action and resistance development of the new compounds. The project has potential to lead to new treatments for infections caused by Gram-positive bacteria, which would have a major impact on public health.

Approach and implementation

** Denna text är maskinöversatt ** The project has been carried out in close collaboration with the ENABLE-2 platform and has included studies of solubility, stability, resistance development, ADMET properties and antibacterial activity. The cooperation between the various parties within the ENABLE-2 platform has been managed via meetings every other week. The project has been evaluated by an external expert committee every four months who have given advice and guidance to the project and on seven occasions recommended continued support for the project.